Evogene stock: Evogene announces AI roadshow. November 2 date matters for Evogene stock||||

Published on 10/23/2026 at 03:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evogene will present ChemPass AI from November 2-5, 2026. The November 10 shareholder vote also matters for Evogene stock.

Governance and commercial milestones

Evogene announced its November 2-5, 2026 AI drug discovery roadshow on October 20, 2026.
First-half 2026 revenue was USD 0.68 million, down 76.40 percent year over year.
Evogene's market capitalization was USD 3.2 million as of October 23, 2026.

EVGN, IL0011050551, Illustration mit AI erstellt.

Evogene Ltd. (IL0011050551) will present its ChemPass AI platform to investors and potential partners during a U.S. roadshow from November 2-5, 2026. According to Evogene, Chief Executive Officer Ofer Haviv will represent the company across the U.S. East Coast.

Roadshow puts ChemPass AI forward

The October 20, 2026 announcement gives Evogene a near-term commercial narrative around generative design for small molecules. The company says ChemPass AI is intended to explore chemical space and optimize candidates for pharmaceutical and agricultural applications, with meetings planned across New York, New Jersey, Philadelphia, Washington, D.C., and Maryland.

For investors, the event is a business-development milestone rather than a revenue announcement. Evogene's first-half 2026 revenue was USD 0.68 million, down 76.40 percent from the prior-year period, while first-half GAAP earnings per share were negative USD 0.63, according to Seeking Alpha on September 28, 2026.

Three dates define the shift

On August 18, 2026, Evogene reported second-quarter and first-half results with USD 0.68 million in first-half revenue, as summarized by Trivano. On September 30, 2026, Nasdaq granted the company until March 29, 2027, to regain compliance with its USD 1.00 minimum bid rule, according to StockTitan. The October 20, 2026 roadshow announcement is the latest event, with the November 2-5, 2026 investor program as its concrete date.

What happens after November 2?

The roadshow begins on November 2, 2026, and runs through November 5, 2026. Evogene's special shareholder meeting is scheduled for November 10, 2026, when investors are expected to consider the cooperation agreement with Pure Capital and board changes, according to StockTitan.

Nasdaq price and valuation

EVGN was last at USD 0.38 on Nasdaq on October 22, 2026 at 4:00 p.m. ET. The market capitalization was USD 3.2 million as of October 23, 2026, while the 52-week range was USD 0.35 to USD 1.33.